Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR) $0.52 +0.04 (+8.25%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.47▼$0.5350-Day Range$0.42▼$0.6152-Week Range$0.41▼$3.19Volume1.13 million shsAverage Volume1.57 million shsMarket Capitalization$100.15 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.86 Rating ScoreUpside/Downside471.4% Upside$3.00 Price TargetShort InterestBearish4.20% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.18Based on 3 Articles This WeekInsider TradingSelling Shares$17,474 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector444th out of 951 stocksPharmaceutical Preparations Industry198th out of 431 stocks 2.9 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on 1 buy rating, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Nektar Therapeutics has a forecasted upside of 471.4% from its current price of $0.53.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.20% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 7.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 2.9 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search Interest37 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 106% compared to the previous 30 days.MarketBeat Follows3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,474.00 in company stock.Percentage Held by InsidersOnly 3.07% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions82.20% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nektar Therapeutics Stock (NASDAQ:NKTR)Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTR Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR)November 26, 2023 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Reduce" by AnalystsDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 25, 2023 | americanbankingnews.comFY2023 Earnings Estimate for Nektar Therapeutics Issued By Zacks Research (NASDAQ:NKTR)November 10, 2023 | benzinga.comNektar Therapeutics Stock (NASDAQ:NKTR) Earnings Dates and Earning CallsNovember 10, 2023 | markets.businessinsider.comPositive Report for Nektar Therapeutics (NKTR) from TD CowenNovember 10, 2023 | msn.comTD Cowen Upgrades Nektar Therapeutics (NKTR)November 9, 2023 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call TranscriptDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS) and Nektar Therapeutics (NKTR)November 8, 2023 | finance.yahoo.comNektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 LossNovember 7, 2023 | benzinga.comRecap: Nektar Therapeutics Q3 EarningsNovember 7, 2023 | markets.businessinsider.comNektar Therapeutics Q3 Loss decreases, but misses estimatesNovember 6, 2023 | benzinga.comA Preview Of Nektar Therapeutics's EarningsOctober 31, 2023 | finance.yahoo.comNektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial MarketsOctober 13, 2023 | finance.yahoo.comNektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV CongressOctober 5, 2023 | msn.comNektar Therapeutics (NKTR) Price Target Increased by 22.34% to 2.93October 2, 2023 | finance.yahoo.comNektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell TherapySeptember 27, 2023 | finance.yahoo.comNektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung CancerSeptember 21, 2023 | benzinga.comDirector at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 SharesSeptember 21, 2023 | benzinga.comNektar Therapeutics Board Member Awarded $59K Worth of Stock OptionsSeptember 13, 2023 | markets.businessinsider.comNektar Therapeutics Reports Promising Data From Phase 1b Study Of RezpegaldesleukinSeptember 7, 2023 | finance.yahoo.comWhy Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?September 6, 2023 | finance.yahoo.comNektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13thAugust 18, 2023 | gurufocus.comRA Capital Management, L.P. Acquires Significant Stake in Nektar TherapeuticsAugust 9, 2023 | finance.yahoo.comNektar Therapeutics (NKTR) Q2 Loss Narrows, Sales MissAugust 8, 2023 | markets.businessinsider.comNektar Therapeutics Q2 Loss decreases, beats estimatesSee More Headlines Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees216Year Founded1990Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+471.4%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-368,200,000.00 Net Margins-332.73% Pretax Margin-329.36% Return on Equity-80.44% Return on Assets-35.10% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.37 Sales & Book Value Annual Sales$92.06 million Price / Sales1.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book0.63Miscellaneous Outstanding Shares190,770,000Free Float184,914,000Market Cap$100.15 million OptionableOptionable Beta0.88 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Howard W. Robin (Age 70)CEO, President & Director Comp: $1.83MMr. Mark A. Wilson (Age 51)Senior VP, Chief Legal Officer & Secretary Comp: $749.99kDr. Jonathan Zalevsky Ph.D. (Age 48)Senior VP & Chief Research and Development Officer Comp: $1.25MMs. Sandra A. Gardiner (Age 57)Chief Financial Officer Vivian WuDirector of Investor Relations & Corporate AffairsMr. Robert BacciSenior Vice President of Human Resources & Facilities OperationsMs. Jennifer RuddockChief Business OfficerDr. Mary Tagliaferri L.Ac. (Age 57)M.D., Chief Medical Officer Dr. Loui T. MadakamutilVP and Head of Discovery & ResearchMore ExecutivesKey CompetitorsEliem TherapeuticsNASDAQ:ELYMGraphite BioNASDAQ:GRPHSelecta BiosciencesNASDAQ:SELBGeneluxNASDAQ:GNLXJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 34,267 shares on 11/17/2023Ownership: 2.571%Howard W RobinSold 19,877 sharesTotal: $9,739.73 ($0.49/share)Jonathan ZalevskySold 9,646 sharesTotal: $4,726.54 ($0.49/share)Diversified Trust CoBought 60,211 shares on 11/17/2023Ownership: 0.032%RA Capital Management L.P.Bought 18,700,000 shares on 11/15/2023Ownership: 9.802%View All Insider TransactionsView All Institutional Transactions NKTR Stock Analysis - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price target for 2024? 7 brokers have issued twelve-month price targets for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 471.4% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2023? Nektar Therapeutics' stock was trading at $2.26 on January 1st, 2023. Since then, NKTR shares have decreased by 76.8% and is now trading at $0.5250. View the best growth stocks for 2023 here. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 80.44% and a negative net margin of 332.73%. During the same period in the prior year, the firm posted ($0.85) EPS. What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.80%), Acadian Asset Management LLC (4.00%), Primecap Management Co. CA (3.77%), Jacobs Levy Equity Management Inc. (2.57%), Monaco Asset Management SAM (2.53%) and AQR Capital Management LLC (1.92%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NKTR) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.